Tumor Organoid Immuno-Oncology Applications

Harness clinically-relevant models for immunotherapy development

3D patient-derived organoid models provide a highly translatable and reproducible platform for in vitro drug development.

To enable immunotherapy assessment using these models, we’ve developed a unique co-culture approach - combining robust and predictive tumor organoids with non-autologous human immune cells. Utilize this organoid immuno-oncology platform to benefit from:

- A highly clinically-relevant 3D in vitro system available for immunotherapy assessment, combining tumor organoids developed using HUB protocols and non-autologous immune cells from healthy patients
- The ability to profile patient population diversity, selecting from over 300 patient-derived tumor organoids across more than 15 different cancer types
- Matched normal/primary and metastatic models with characterization data accessible via OrganoidBase
- A highly scalable system, allowing the assessment of multiple cell donors and tumor model combinations concurrently, to overcome donor-to-donor variability and the limited availability of autologous patient material
- Faster results compared with more complex in vivo systems
- Customization through organoid engineering to establish new immunotherapy models, such as expressing specific CAR-T targets of choice

Organoid and immune cell co-culture provides flexibility across applications for proof of concept and mechanism of action studies, including:

- Evaluating the potency of immunotherapies using non-autologous allogenic T cell assays with optimized conditions
- Assessing tumor organoid killing by allogenic T, CAR-T, or CAR-NK cells
- Testing ADC, ADCC, CDC, and CDCP effects
- Evaluating tumor reactivity of CAR-T and TCR cells
- Profiling immunotherapy target gene expression on tumor organoids or identifying antigens of interest (such as tumor-associated antigens, immune checkpoint molecules)

Available readouts
- Morphology evaluation
- Luciferase reporter detection
- Flow analysis (live/dead)
- Cytokine production measurement

Test agents
- CAR-T cells
- CAR-NK cells
- T cell engagers

Mechanism of action
- T cell mediated
- ADCC, CDC, CDCP
- ADC

Immune cells
- TILs
- Macrophages
- Dendritic cells
- Other TME components

Organoid

HUB ORGANOID

Organoid

Immune cells

• TILs
• Macrophages
• Dendritic cells
• Other TME components

Mechanism of action

• T cell mediated
• ADCC, CDC, CDCP
• ADC

Test agents

• CAR-T cells
• CAR-NK cells
• T cell engagers

Available readouts

• Morphology evaluation
• Luciferase reporter detection
• Flow analysis (live/dead)
• Cytokine production measurement

Schedule Scientific Consultation
Request a consultation to discuss your project.
consultation@crownbio.com

Explore Scientific Data
Log in into OrganoidBase to review organoid model data.
https://organoid.crownbio.com

Contact Sales
US: +1.855.827.6968
UK: +44 (0)1870 166 6234
busdev@crownbio.com

+1.855.827.6968 | busdev@crownbio.com | www.crownbio.com